

## Special Issue

# Advances in Antibody–Drug Conjugates (ADCs) in Cancers

### Message from the Guest Editor

Antibody–drug conjugates (ADCs) are targeted anticancer therapeutics comprising an antibody conjugated to a cytotoxic payload through a linker. This composition confers ADCs with improved specificity and less potential for side-effects than traditional chemotherapy regimens. Several ADCs have been approved for the treatment of both hematological malignancies and solid tumors, and numerous more are in clinical trials. While the composition of ADCs is straightforward, many factors, including antigen affinity/avidity/specificity, hydrophobicity of the construct, stability of the linker, atypical glycosylation patterns, and the presence of specific amino acid residues in the complementarity-determining region, impact the in vivo disposition and therapeutic efficacy of ADCs. This Special Issue will focus on the drug delivery aspects of ADCs and the relationship between the structural features and in vivo disposition of ADCs.

---

### Guest Editor

Prof. Dr. Jayanth Panyam  
Professor and Dean, Temple University School of Pharmacy, 3307  
North Broad Street, Philadelphia, PA 19140, USA

---

### Deadline for manuscript submissions

closed (20 March 2026)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/21981](https://mdpi.com/si/21981)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)